Literature DB >> 29880608

In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.

Montserrat Pérez-Salvia1, Eneko Aldaba2, Yosu Vara2, Myriam Fabre3, Cristina Ferrer3, Carme Masdeu4, Aizpea Zubia5, Eider San Sebastian5, Dorleta Otaegui6, Pere Llinàs-Arias1, Margalida Rosselló-Tortella1, Maria Berdasco1, Catia Moutinho1, Fernando Setien1, Alberto Villanueva7, Eva González-Barca8, Josep Muncunill9, José-Tomás Navarro9, Miguel A Piris10, Fernando P Cossio5, Manel Esteller11,12,13,14.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29880608      PMCID: PMC6278978          DOI: 10.3324/haematol.2018.189241

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

Authors:  Stephen E Spurgeon; Brian G Till; Peter Martin; Andre H Goy; Martin P Dreyling; Ajay K Gopal; Michael LeBlanc; John P Leonard; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; Brad S Kahl; Mitchell R Smith
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

Review 2.  Targeting bromodomains: epigenetic readers of lysine acetylation.

Authors:  Panagis Filippakopoulos; Stefan Knapp
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

3.  HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.

Authors:  Malgorzata Bobrowicz; Michal Dwojak; Beata Pyrzynska; Joanna Stachura; Angelika Muchowicz; Elise Berthel; Nicole Dalla-Venezia; Mieszko Kozikowski; Marta Siernicka; Nina Miazek; Piotr Zapala; Antoni Domagala; Kamil Bojarczuk; Agata Malenda; Joanna Barankiewicz; Agnieszka Graczyk-Jarzynka; Agnieszka Zagozdzon; Magdalena Gabrysiak; Jean-Jacques Diaz; Marta Karp; Ewa Lech-Maranda; Malgorzata Firczuk; Krzysztof Giannopoulos; Dimitar G Efremov; Luca Laurenti; Dunja Baatout; Lukas Frenzel; Agata Malinowska; Mikolaj Slabicki; Thorsten Zenz; Abdessamad Zerrouqi; Jakub Golab; Magdalena Winiarska
Journal:  Blood       Date:  2017-08-22       Impact factor: 22.113

4.  Formation of γ-oxoacids and 1H-pyrrol-2(5H)-ones from α,β-unsaturated ketones and ethyl nitroacetate.

Authors:  Maialen Aginagalde; Tamara Bello; Carme Masdeu; Yosu Vara; Ana Arrieta; Fernando P Cossío
Journal:  J Org Chem       Date:  2010-11-05       Impact factor: 4.354

5.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.

Authors:  Orion M Howard; John G Gribben; Donna S Neuberg; Michael Grossbard; Christina Poor; Milos J Janicek; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

6.  HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo.

Authors:  Yu Zhang; Na Li; Cécile Caron; Gabriele Matthias; Daniel Hess; Saadi Khochbin; Patrick Matthias
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

7.  A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.

Authors:  Tint Lwin; Xiaohong Zhao; Fengdong Cheng; Xinwei Zhang; Andy Huang; Bijal Shah; Yizhuo Zhang; Lynn C Moscinski; Yong Sung Choi; Alan P Kozikowski; James E Bradner; William S Dalton; Eduardo Sotomayor; Jianguo Tao
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

Review 8.  Targeting the cancer epigenome for therapy.

Authors:  Peter A Jones; Jean-Pierre J Issa; Stephen Baylin
Journal:  Nat Rev Genet       Date:  2016-09-15       Impact factor: 53.242

9.  Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease.

Authors:  Nambirajan Govindarajan; Pooja Rao; Susanne Burkhardt; Farahnaz Sananbenesi; Oliver M Schlüter; Frank Bradke; Jianrong Lu; André Fischer
Journal:  EMBO Mol Med       Date:  2012-11-26       Impact factor: 12.137

10.  Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer.

Authors:  Montserrat Pérez-Salvia; Laia Simó-Riudalbas; Pere Llinàs-Arias; Laura Roa; Fernando Setien; Marta Soler; Manuel Castro de Moura; James E Bradner; Eva Gonzalez-Suarez; Catia Moutinho; Manel Esteller
Journal:  Oncotarget       Date:  2017-05-29
View more
  4 in total

Review 1.  HDAC6: A unique HDAC family member as a cancer target.

Authors:  Sumeet Kaur; Prerna Rajoria; Madhu Chopra
Journal:  Cell Oncol (Dordr)       Date:  2022-08-29       Impact factor: 7.051

Review 2.  The DNA methylation landscape of hematological malignancies: an update.

Authors:  Pedro Blecua; Laura Martinez-Verbo; Manel Esteller
Journal:  Mol Oncol       Date:  2020-07-03       Impact factor: 6.603

3.  Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma.

Authors:  Jaione Auzmendi-Iriarte; Ander Saenz-Antoñanzas; Idoia Mikelez-Alonso; Estefania Carrasco-Garcia; Maitena Tellaetxe-Abete; Charles H Lawrie; Nicolás Sampron; Aitziber L Cortajarena; Ander Matheu
Journal:  Cell Death Dis       Date:  2020-06-02       Impact factor: 8.469

4.  HDAC6 regulates microtubule stability and clustering of AChRs at neuromuscular junctions.

Authors:  Alexis Osseni; Aymeric Ravel-Chapuis; Jean-Luc Thomas; Vincent Gache; Laurent Schaeffer; Bernard J Jasmin
Journal:  J Cell Biol       Date:  2020-08-03       Impact factor: 10.539

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.